Financial Ratios Neurogene Inc.

Equities

NGNE

US64135M1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/02/2026 GMT			5-day change	1st Jan Change
17.00 ^USD	-3.52%		-3.19%	-17.48%

02-04	Neurogene announces inducement grant under Nasdaq Listing Rule	RE
01-12	Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-In-Class Gene Therapy for Rett Syndrome	CI

0527a173afe7593950c205.NUNw5z8tMV_HPf2PWMhyelEpfn3qNKGCB0SXv2GUK_U.RglFik1fWj2SD5O_O5oTMQNMFQuOfdTxQX3m5VLiZsFibgqNTFR8BbQEjg

Published financial data: NEUROGENE INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024
Revenues	-	-	-	925K
Total Revenues	-	-	-	925K
Cost of Goods Sold, Total	42.26M	47.5M	44.39M	60.82M
Gross Profit	-42.26M	-47.5M	-44.39M	-59.89M
Selling General & Admin Expenses, Total	8.27M	9.01M	11.19M	22.61M
Other Operating Expenses, Total	8.27M	9.01M	11.19M	22.61M
Operating Income	-50.53M	-56.52M	-55.58M	-82.5M
Interest Expense, Total	-	-2K	-12K	-12K
Interest And Investment Income	17K	1.34M	2.95M	8.47M
Net Interest Expenses	17K	1.34M	2.94M	8.46M
Other Non Operating Income (Expenses)	-	-7K	-28K	-994K
EBT, Excl. Unusual Items	-50.52M	-55.19M	-52.67M	-75.04M
Asset Writedown	-	-	-	-100K
Other Unusual Items	-	-	16.36M	-
EBT, Incl. Unusual Items	-50.52M	-55.19M	-36.32M	-75.14M
Earnings From Continuing Operations	-50.52M	-55.19M	-36.32M	-75.14M
Net Income to Company	-50.52M	-55.19M	-36.32M	-75.14M
Net Income - (IS)	-50.52M	-55.19M	-36.32M	-75.14M
Preferred Dividend and Other Adjustments	-	-	-49.97M	-
Net Income to Common Incl Extra Items	-50.52M	-55.19M	13.65M	-75.14M
Net Income to Common Excl. Extra Items	-50.52M	-55.19M	13.65M	-75.14M
Per Share Items
Net EPS - Basic	-12.47	-10.58	27.76	-4.28
Basic EPS - Continuing Operations	-12.47	-10.58	27.76	-4.28
Basic Weighted Average Shares Outstanding	4.05M	5.22M	492K	17.57M
Net EPS - Diluted	-12.47	-10.58	2.93	-4.28
Diluted EPS - Continuing Operations	-12.47	-10.58	2.93	-4.28
Diluted Weighted Average Shares Outstanding	4.05M	5.22M	4.66M	17.57M
Normalized Basic EPS	-7.79	-6.61	-66.93	-2.67
Normalized Diluted EPS	-7.79	-6.61	-7.07	-2.67
Supplemental Items
EBITDA	-49.59M	-53.32M	-52.29M	-79.26M
EBITA	-50.53M	-56.52M	-55.58M	-82.5M
EBIT	-50.53M	-56.52M	-55.58M	-82.5M
EBITDAR	-44.85M	-49.66M	-50.99M	-76.36M
Normalized Net Income	-31.57M	-34.49M	-32.92M	-46.9M
Interest on Long-Term Debt	-	2K	12K	12K
Supplemental Operating Expense Items
General and Administrative Expenses	8.27M	9.01M	11.19M	22.61M
Research And Development Expense From Footnotes	42.26M	47.5M	44.39M	60.92M
Net Rental Expense, Total	4.74M	3.67M	1.3M	2.9M
Imputed Operating Lease Interest Expense	-	11.85K	12.64K	20.32K
Imputed Operating Lease Depreciation	-	3.65M	1.28M	2.88M
Stock-Based Comp., COGS (Total)	474K	732K	897K	4.51M
Stock-Based Comp., G&A Exp. (Total)	422K	520K	521K	3.81M
Total Stock-Based Compensation	896K	1.25M	1.42M	8.32M

Fiscal Period: December	2021	2022	2023	2024
Assets
Cash And Equivalents	70.54M	82.02M	148M	137M
Short Term Investments	-	-	48.95M	176M
Total Cash And Short Term Investments	70.54M	82.02M	197M	312M
Other Receivables	790K	990K	600K	648K
Total Receivables	790K	990K	600K	648K
Prepaid Expenses	1.91M	1.08M	1.5M	1.89M
Other Current Assets, Total	711K	630K	1.1M	981K
Total Current Assets	73.96M	84.72M	200M	316M
Gross Property Plant And Equipment	29.1M	29.31M	28.96M	29.66M
Accumulated Depreciation	-1.57M	-4.77M	-8.01M	-11.17M
Net Property Plant And Equipment	27.53M	24.55M	20.95M	18.49M
Other Long-Term Assets, Total	-	-	1.27M	1.31M
Total Assets	101M	109M	223M	336M
Liabilities
Accounts Payable, Total	5.63M	625K	2.6M	1.34M
Accrued Expenses, Total	4.35M	5.16M	16.76M	9.39M
Current Portion of Leases	610K	702K	2.6M	3M
Other Current Liabilities	267K	167K	1.02M	1.43M
Total Current Liabilities	10.86M	6.65M	22.97M	15.16M
Long-Term Leases	4.6M	3.99M	12.37M	9.43M
Other Non Current Liabilities	-	-	1.21M	769K
Total Liabilities	15.46M	10.64M	36.55M	25.36M
Preferred Stock Convertible	178M	244M	-	-
Total Preferred Equity	178M	244M	-	-
Common Stock, Total	1K	1K	-	-
Additional Paid In Capital	3.77M	5.1M	373M	573M
Retained Earnings	-95.65M	-151M	-187M	-262M
Total Common Equity	-91.88M	-146M	186M	310M
Total Equity	86.03M	98.63M	186M	310M
Total Liabilities And Equity	101M	109M	223M	336M
Supplemental Items
ECS Total Shares Outstanding on Filing Date	4.05M	5.67M	12.85M	14.93M
ECS Total Common Shares Outstanding	4.05M	5.67M	12.82M	14.85M
Book Value / Share	-22.68	-25.72	14.51	20.89
Tangible Book Value	-91.88M	-146M	186M	310M
Tangible Book Value Per Share	-22.68	-25.72	14.51	20.89
Total Debt	5.21M	4.69M	14.97M	12.43M
Net Debt	-65.34M	-77.33M	-182M	-300M
Debt Equivalent Oper. Leases	37.89M	29.33M	10.36M	23.19M
Account Code - Inventory Valuation	-	3	3	3
Machinery, Total	6.01M	9.04M	9.3M	9.6M
Full Time Employees	-	82	91	107

Fiscal Period: December	2021	2022	2023	2024
Net Income	-50.52M	-55.19M	-36.32M	-75.14M
Depreciation & Amortization - CF	947K	3.2M	3.3M	3.25M
Depreciation & Amortization, Total	947K	3.2M	3.3M	3.25M
(Gain) Loss on Sale of Investments - (CF)	-	-	-105K	-2.42M
Asset Writedown & Restructuring Costs	-	-	-	91K
Stock-Based Compensation (CF)	896K	1.25M	1.42M	8.32M
Other Operating Activities, Total	679K	612K	-15.69M	1.26M
Change In Accounts Payable	2.98M	-3.61M	667K	-77K
Change in Other Net Operating Assets	-1.39M	912K	-4.69M	-5.88M
Cash from Operations	-46.4M	-52.82M	-51.42M	-70.6M
Capital Expenditure	-18.37M	-2.23M	-321K	-808K
Cash Acquisitions	-	-	20.96M	-
Investment in Marketable and Equity Securities, Total	-	-	5M	-124M
Cash from Investing	-18.37M	-2.23M	25.64M	-125M
Long-Term Debt Repaid, Total	-	-1K	-29K	-52K
Total Debt Repaid	-	-1K	-29K	-52K
Issuance of Common Stock	287K	73K	168K	191M
Issuance of Preferred Stock	50.78M	66.46M	-	-
Other Financing Activities, Total	-	-	92.34M	-7.14M
Cash from Financing	51.06M	66.53M	92.48M	184M
Net Change in Cash	-13.71M	11.48M	66.7M	-11.79M
Supplemental Items
Cash Interest Paid	-	2K	12K	12K
Levered Free Cash Flow	-	-36.69M	-16.42M	-49.36M
Unlevered Free Cash Flow	-	-36.69M	-16.42M	-49.35M
Change In Net Working Capital	-	3.58M	-13.93M	8.54M
Net Debt Issued / Repaid	-	-1K	-29K	-52K

Fiscal Period: December	2021	2022	2023	2024
Profitability
Return on Assets	-	-33.52	-20.94	-18.47
Return on Total Capital	-	-36.31	-22.83	-19.69
Return On Equity %	-	-59.77	-25.52	-30.28
Return on Common Equity	-	46.45	67.79	-30.28
Margin Analysis
Gross Profit Margin %	-	-	-	-6.47K
SG&A Margin	-	-	-	2.44K
EBITDA Margin %	-	-	-	-8.57K
EBITA Margin %	-	-	-	-8.92K
EBIT Margin %	-	-	-	-8.92K
Income From Continuing Operations Margin %	-	-	-	-8.12K
Net Income Margin %	-	-	-	-8.12K
Net Avail. For Common Margin %	-	-	-	-8.12K
Normalized Net Income Margin	-	-	-	-5.07K
Levered Free Cash Flow Margin	-	-	-	-5.34K
Unlevered Free Cash Flow Margin	-	-	-	-5.33K
Asset Turnover
Asset Turnover	-	-	-	0
Fixed Assets Turnover	-	-	-	0.05
Short Term Liquidity
Current Ratio	6.81	12.74	8.72	20.84
Quick Ratio	6.57	12.48	8.61	20.65
Operating Cash Flow to Current Liabilities	-4.27	-7.94	-2.24	-4.66
Average Days Payable Outstanding	-	24.03	13.24	11.83
Long Term Solvency
Total Debt/Equity	6.05	4.75	8.05	4
Total Debt / Total Capital	5.71	4.54	7.45	3.85
LT Debt/Equity	5.35	4.04	6.65	3.04
Long-Term Debt / Total Capital	5.04	3.86	6.15	2.92
Total Liabilities / Total Assets	15.23	9.74	16.42	7.55
EBIT / Interest Expense	-	-28.26K	-4.63K	-6.88K
EBITDA / Interest Expense	-	-24.83K	-4.25K	-6.36K
(EBITDA - Capex) / Interest Expense	-	-25.94K	-4.28K	-6.43K
Total Debt / EBITDA	-0.12	-0.09	-0.29	-0.16
Net Debt / EBITDA	1.46	1.56	3.57	3.93
Total Debt / (EBITDA - Capex)	-0.08	-0.09	-0.29	-0.16
Net Debt / (EBITDA - Capex)	1.03	1.49	3.55	3.89
Growth Over Prior Year
Gross Profit, 1 Yr. Growth %	-	12.4	-6.55	34.91
EBITDA, 1 Yr. Growth %	-	7.53	-1.93	51.59
EBITA, 1 Yr. Growth %	-	11.84	-1.65	48.44
EBIT, 1 Yr. Growth %	-	11.84	-1.65	48.44
Earnings From Cont. Operations, 1 Yr. Growth %	-	9.25	-34.2	106.91
Net Income, 1 Yr. Growth %	-	9.25	-34.2	106.91
Normalized Net Income, 1 Yr. Growth %	-	9.25	-4.56	42.47
Diluted EPS Before Extra, 1 Yr. Growth %	-	-15.18	-102.09	-246.08
Net Property, Plant and Equip., 1 Yr. Growth %	-	-10.84	-14.64	-11.74
Total Assets, 1 Yr. Growth %	-	7.66	103.7	50.84
Tangible Book Value, 1 Yr. Growth %	-	58.63	-227.64	66.85
Common Equity, 1 Yr. Growth %	-	58.63	-227.64	66.85
Cash From Operations, 1 Yr. Growth %	-	13.84	-2.65	37.3
Capital Expenditures, 1 Yr. Growth %	-	-87.86	-85.61	151.71
Levered Free Cash Flow, 1 Yr. Growth %	-	-	-55.23	200.53
Unlevered Free Cash Flow, 1 Yr. Growth %	-	-	-55.25	200.62
Compound Annual Growth Rate Over Two Years
Gross Profit, 2 Yr. CAGR %	-	-	2.49	12.28
EBITDA, 2 Yr. CAGR %	-	-	2.69	21.92
EBITA, 2 Yr. CAGR %	-	-	4.88	20.82
EBIT, 2 Yr. CAGR %	-	-	4.88	20.82
Earnings From Cont. Operations, 2 Yr. CAGR %	-	-	-15.21	16.69
Net Income, 2 Yr. CAGR %	-	-	-15.21	16.69
Normalized Net Income, 2 Yr. CAGR %	-	-	2.11	16.61
Diluted EPS Before Extra, 2 Yr. CAGR %	-	-	-51.52	-82.51
Net Property, Plant and Equip., 2 Yr. CAGR %	-	-	-12.76	-13.2
Total Assets, 2 Yr. CAGR %	-	-	48.09	75.29
Tangible Book Value, 2 Yr. CAGR %	-	-	42.29	45.93
Common Equity, 2 Yr. CAGR %	-	-	42.29	45.93
Cash From Operations, 2 Yr. CAGR %	-	-	5.27	15.61
Capital Expenditures, 2 Yr. CAGR %	-	-	-86.78	-39.81
Levered Free Cash Flow, 2 Yr. CAGR %	-	-	-	15.99
Unlevered Free Cash Flow, 2 Yr. CAGR %	-	-	-	15.99
Compound Annual Growth Rate Over Three Years
Gross Profit, 3 Yr. CAGR %	-	-	-	12.32
EBITDA, 3 Yr. CAGR %	-	-	-	16.92
EBITA, 3 Yr. CAGR %	-	-	-	17.75
EBIT, 3 Yr. CAGR %	-	-	-	17.75
Earnings From Cont. Operations, 3 Yr. CAGR %	-	-	-	14.15
Net Income, 3 Yr. CAGR %	-	-	-	14.15
Normalized Net Income, 3 Yr. CAGR %	-	-	-	14.1
Diluted EPS Before Extra, 3 Yr. CAGR %	-	-	-	-29.98
Net Property, Plant and Equip., 3 Yr. CAGR %	-	-	-	-12.42
Total Assets, 3 Yr. CAGR %	-	-	-	49
Tangible Book Value, 3 Yr. CAGR %	-	-	-	50.05
Common Equity, 3 Yr. CAGR %	-	-	-	50.05
Cash From Operations, 3 Yr. CAGR %	-	-	-	15.02
Capital Expenditures, 3 Yr. CAGR %	-	-	-	-64.7